MedTrace Logo

Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer

NCT01832870 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2017-08-24

No results posted yet for this study

Summary

This is a clinical trial designed to quantify the immune response and determine the tolerability and side effects of sipuleucel-T when given in combination with ipilimumab for patients with advanced prostate cancer.

Conditions

Interventions

DRUG

sipuleucel-T

DRUG

ipilimumab

Sponsors & Collaborators

  • Prostate Oncology Specialists, Inc.

    lead OTHER

Principal Investigators

  • Mark Scholz, MD · Prostate Oncology Specialists, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-02-29
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01832870 on ClinicalTrials.gov